Glucose and C-peptide changes in the perionset period of type 1 diabetes in the diabetes prevention trial-type 1

Diabetes Care

Volumn 31, Issue 11, 2008, Pages 2188-2192

  Sosenko, Jay M ^a   Palmer, Jerry P ^b   Rafkin Mervis, Lisa ^b   Krischer, Jeffrey P ^c   Cuthbertson, David ^c   Matheson, Della ^b   Skyler, Jay S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN ZINC SUSPENSION; RECOMBINANT HUMAN INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; ORAL GLUCOSE TOLERANCE TEST; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SCHOOL CHILD; TREATMENT RESPONSE; VALIDATION PROCESS; BLOOD; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; METABOLISM;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; PREDIABETIC STATE;

EID: 56649115489     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0935     Document Type: Article

References (15)

1. Greenbaum CJ, Cuthbertson D, Krischer JP, the Diabetes Prevention Trial of Type 1 Diabetes Study Group: Type 1 diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 50:470-476, 2001
2. Sosenko J, Palmer JP, Greenbaum CJ, Ma- hon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, the Diabetes Prevention Trial-Type 1 Study Group: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes. Diabetes Care 30:38-42, 2007
3. Sosenko J, Palmer JP, Greenbaum CJ, Ma- hon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, the Diabetes Prevention Trial-Type 1 Study Group. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 29:643-649, 2006
4. Snorgaard O, Lassen LH, Binder C: Homogeneity in pattern of decline of β-cell function in IDDM: prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15:1009-1013, 1992
5. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β -cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264, 2004
6. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC: Insulin secretion in type 1 diabetes. Diabetes 53:426-433, 2004
7. Sherry NA, Tsai EB, Herold KC: Natural history of β -cell function in type 1 diabetes. Diabetes 54 (Suppl. 2):S32-S39, 2005
8. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1691, 2002
9. Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 28:1068-1076, 2005
10. Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz DA, DPT-1 Study Group: Participant and parent experiences in the parenteral insulin arm of the Diabetes Prevention Trial for Type 1 Diabetes. Diabetes Care 30:2193-2198, 2007
11. Faber OK, Binder C: β -Cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 13:263-268, 1977
12. Komulainen J, Knip M, Lounamaa R, Vähäsalo P, Karjalainen J, Sabbah E, Åker- blom HK, Childhood Diabetes in Finland Study Group: Poor β -cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabet Med 14:532-537, 1997
13. O'Leary LA, Dorman JS, LaPorte RE, Orchard TJ, Becker DJ, Kuller LH, Eberhardt MS, Cavender DE, Rabin BS, Drash AL: Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies? Diabetes Res Clin Pract 14:183-190, 1991
14. Ludvigsson J, Heding LG, Larsson Y, Le- ander E: C-peptide in juvenile diabetics beyond the postinitial remission period: relation to clinical manifestation at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 66:177-184, 1977
15. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes. N Engl J Med 350:550-555, 1989